Analysis – Page 66 – Goldea Capital

SONORO GOLD ANNOUNCES LETTERS OF INTENT TO ACQUIRE ADJACENT MINERAL CONCESSIONS TO FURTHER EXPAND THE CERRO CALICHE GOLD PROJECT

Written by Customer Service on May 12, 2026. Posted in Public Companies.

VANCOUVER, Canada, May 12, 2026 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that its wholly owned Mexican subsidiary, Minera Mar de Plata (“MMP”), has executed three binding Letters of Intent (the “LOIs”) with two residents of Sonora, Mexico (the “Vendors”) to acquire a 100% interest in 24 mineral concessions, and up to a 51% interest in five additional mineral concessions, located adjacent to the Company’s Cerro Caliche gold project in Sonora, Mexico. The Vendors are at arm’s length to the Company and to its associates and affiliates. Sonoro believes the acquisition is a strategic opportunity to potentially demonstrate the Cerro Caliche project as being part of a larger gold epithermal system, with wide-scale potential to host multiple mineralized...

Rezolve Ai partners with $30bn+ revenue global technology leader Tata Consultancy Services to bring its AI-powered commerce platform to enterprise clients worldwide

Written by Customer Service on May 12, 2026. Posted in Public Companies.

TCS to resell Rezolve’s AI-powered commerce platform globally, significantly expanding Rezolve’s route to market through one of the world’s largest digital transformation organizations NEW YORK and MUMBAI, India, May 12, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce infrastructure, and Tata Consultancy Services (“TCS”), the $30bn+ revenue global IT services, consulting and business solutions leader, today announced a global strategic partnership designed to accelerate the worldwide rollout of agentic commerce. Under the agreement, TCS will resell Rezolve’s AI-powered commerce platform to enterprise clients globally, giving Rezolve access to one of the broadest client relationships, delivery capabilities and digital transformation footprints in the world. The partnership marks a major...

Biometric Identity and Authentication Provider BIO-key to host Q1’26 Investor Webcast Monday, May 18th at 10am ET

Written by Customer Service on May 12, 2026. Posted in Public Companies.

HOLMDEL, N.J., May 12, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, will host its Q1’26 investor call and webcast on Monday, May 18th at 10 a.m. ET. Mike DePasquale, Chairman & CEO and Cecilia Welch, CFO will lead the call and Q&A session.Call/Webcast Details Date / Time: Monday, May 18th at 10 a.m. ETCall Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 Int’lLive Webcast / Replay: Webcast & Replay Link – Available for 3 months.Audio Replay: 1-855-669-9658 U.S. or 1-412-317-0088 Int’l; code 1165470About BIO-key International, Inc. (www.BIO-key.com) BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management...

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 11 05 2026] – (CGWL)

Written by Customer Service on May 12, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

Written by Customer Service on May 12, 2026. Posted in Mergers And Acquisitions.

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition – – 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million – STOUGHTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced that it has completed the acquisition of AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years...

ZenaTech Targets Gulf State Defense Markets with Lviv-Based Phoenix Aero Counter-UAS and Interceptor Drone Production

Written by Customer Service on May 12, 2026. Posted in Public Companies.

Western Ukraine manufacturing base positioned to address accelerating GCC demand for combat-validated, cost-effective counter-UAS drone systems. VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces that its new Ukrainian subsidiary, Phoenix Aero LLC, is expected to serve as a manufacturing and export base for counter-UAS and interceptor drone systems targeted to defense customers across Gulf Cooperation Council (GCC) countries. These countries include Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman and have demonstrated increasing demand for scalable, lower-cost...

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

Written by Customer Service on May 12, 2026. Posted in Public Companies.

iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineering Findings underscore the intrinsic biology of iNKT cells and the manufacturing scale for a broadly deployable cell therapy capable of expansion in multiple disease indications without disease-specific engineering Clinical activity in both settings: tumor responses including complete metastatic remission in oncology; improved survival and pathogen clearance in severe ARDS Data support advancement into a randomized Phase 2 trial in acute lung injury (C-1300-02); preliminary data expected in 2026NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing...

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Cumulative cash, cash equivalents and marketable securities expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to severe acne SAN MATEO, Calif., May 12, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2026, and provided corporate updates. “Our recent strategic decision to focus on dermatology...

Nayax Reports First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Revenue of $106.9 million, revenue growth of 32% Organic revenue growth of 26% (1) Net income of $1.3 million with Adjusted EBITDA of $13.9 million (1) Company reaffirms full year 2026 guidance HERZLIYA, Israel, May 12, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX, TASE: NYAX), a global commerce payments and loyalty platform designed to help merchants scale their business, today announced its financial results for the first quarter ended March 31, 2026. “We had an excellent start to 2026, with strong operational and financial results across the business. We continued to scale our platform, expand our installed base, and drive transaction activity, all of which reinforces the more predictable and profitable recurring revenue contribution to our business. Revenue grew 32% to $107 million, with organic revenue growth of 26%. Furthermore,...

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

LONDON, May 12, 2026 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments. “Based on extensive analysis of data across the two global Phase 3 studies of setrusumab in osteogenesis imperfecta in collaboration with our partner Ultragenyx, we believe there is basis to engage with the regulatory agencies to determine if there is a path forward in pediatric patients. These interactions have been initiated, and we plan to provide updates once we have some definitive feedback. We continue to believe that setrusumab has the potential to provide meaningful benefit for people living with OI, a condition...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals